Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for multiple system atrophy and amyotrophic lateral sclerosis.
If you currently work at this organization, click the “Do you work here?” button to request editing privileges.
This SponsorPitch page is about Biohaven and contains information about this organization's sponsorship activity, sponsorship decision makers and sponsorship preferences. This page is not endorsed by or affiliated with Biohaven, though it may be actively managed and updated by company representatives. If you currently work at this organization, click the Manage Sponsor button to request management privileges. . All trademarks, service marks and copyrights are property of their respective owners.
Please log in to access this feature. Don't have an account? Sign up today!